Quick Answer
Amylyx Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Amylyx Pharmaceuticals, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $0.00 | -100.0% |
| 2024 | $87.37M | -77.1% |
| 2023 | $380.79M | +1612.9% |
| 2022 | $22.23M | +7700.0% |
| 2021 | $285.0K | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | -100.0% | — |
| June 30, 2025 | $0.00 | +100.0% | — |
| March 31, 2025 | $0.00 | -100.0% | -100.0% |
| September 30, 2024 | $416.0K | -99.6% | +140.7% |
| June 30, 2024 | -$1.02M | -101.0% | -101.2% |
| March 31, 2024 | $88.64M | +24.1% | -13.7% |
| September 30, 2023 | $102.69M | +29666.1% | +4.6% |
| June 30, 2023 | $98.22M | — | +37.5% |
- Amylyx Pharmaceuticals, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Over the 2021–2025 period, Amylyx Pharmaceuticals, Inc.’s total revenue has declined by 100.0% (from $285.0 thousand to $0.00).
- The most recent figure is from Amylyx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: